Imetelstat could be part initial therapy and maintence thrapy in 90% of all cancers. Whether as a single agent or in combination with other drugs, it looks like a telomerase inhibitor can have a role in cancer treatment. The Phase II trial will answer that question at the end of 2012. If so, Imetelstat may be the first and only drug that has the benefit that hits CSCs. It could be the blockbuster of all time in cancer. That's why GERN decided it could not afford to expend its limited resources on ESCs. It's still very dispointing but with limited funds a choice had to be made.
Good luck in this rigged casino,
No comments:
Post a Comment